Biotech Movers: Shire Falls on Stem Cell Program Transfer; Calithera, Synergy Up on FDA Approvals – TheStreet.com
|
Biotech Movers: Shire Falls on Stem Cell Program Transfer; Calithera, Synergy Up on FDA Approvals
TheStreet.com Calithera Biosciences (CALA) was up to $16.10, a spike of 70 cents or 4.55%, after the FDA designated the company's lead product candidate, CB-839, in combination with Novartis' AFINITOR for Fast Track review for the treatment of metastatic renal cell … |
